22 June 2022
Directa Plus plc
("Directa Plus" or the "Company")
Grant of Italian Patent for Filtration Applications
Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that the Company has been granted an Italian patent covering the use of the Company's G+® pristine graphene nanoplatelets applied to textile substrates for high bacterial filtration efficiency media for filtration applications. The priority date for the patent is 25 May 2020.
G+® applied to textile substrates provides proven antibacterial and antiviral (including anti-SARS-CoV-2) performance. The target filtration market applications cover both medical and industrial use. Directa Plus started work on air filtration in 2020 with a signature project that successfully supplied face masks with anti-SARS-CoV-2 protection. This work led quickly into exploring industrial filtration applications starting with the automotive and HVAC (heating, ventilation and air conditioning) markets. Directa Plus, as already announced, has partnered with a leading worldwide supplier of non-woven textile materials to develop a suite of new products for automotive and industrial applications based on the antimicrobial properties (antibacterial and antiviral), thermal comfort and electrical conductivity properties of G+® enhanced fabrics.
Following the grant of the patent, Directa Plus's IP portfolio comprises 20 patent families with 73 patents granted and 28 patents pending.
Commenting, Giulio Cesareo, Founder and CEO of Directa Plus, said: "The grant of a patent for a new market vertical demonstrates the speed with which we can enter existing high potential markets to supply innovative new products. The international filtration markets are large and we believe that there will be significant demand for proven antimicrobial products which we aim to launch quickly with our industrial partners."
For further information please visit http://www.directa-plus.com/ or contact:
| Directa Plus plc | +39 02 36714458 |
| Giulio Cesareo, CEO / Giorgio Bonfanti, CFO | |
| | |
| Cenkos Securities plc (Nominated Adviser and Joint Broker) | +44 131 220 6939 |
| Neil McDonald / Adam Rae | |
| | |
| Singer Capital Markets (Joint Broker) | +44 20 7496 3069 |
| Rick Thompson / Phil Davies | |
| | |
| Tavistock (Financial PR and IR) | +44 20 7920 3150 |
| Simon Hudson / Heather Armstrong | |
About Directa Plus
Directa Plus (www.directa-plus.com) is one of the largest producers and suppliers of graphene-based products for use in consumer and industrial markets. The Company's graphene manufacturing capability uses proprietary patented technology based on a plasma super expansion process. Starting from natural graphite, each step of Directa Plus' production process - expansion, exfoliation and drying - creates graphene-based materials and hybrid graphene materials ready for a variety of uses and available in various forms such as powder, liquid and paste.
This proprietary production process uses a physical process, rather than a chemical process, to process graphite into pristine graphene nanoplatelets, which enables Directa Plus to offer a sustainable, non-toxic product, without unwanted by-products. Directa Plus' products are made of hybrid graphene materials and graphene nano-platelets. The products (marketed as G+®) have multiple applications due to its properties. These G+® products can be categorised into various families, with different products being suitable for specific practical applications.
Directa Plus was established in 2005 and is based in Lomazzo (Como, Italy) and has been listed on the AIM market of the London Stock Exchange since May 2016. The Company holds the Green Economy Mark from London Stock Exchange which recognises companies that contribute to the global green economy.
-ends-
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.